Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SOT109 |
| Synonyms | |
| Therapy Description |
SOT109 is an antibody-drug conjugate (ADC) comprising an antibody targeting CDH17 linked to exatecan, which potentially inhibits growth of CDH17-expressing tumors (Cancer Res (2025) 85 (8_Supplement_1): 5469). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SOT109 | SOT-109|SOT 109 | SOT109 is an antibody-drug conjugate (ADC) comprising an antibody targeting CDH17 linked to exatecan, which potentially inhibits growth of CDH17-expressing tumors (Cancer Res (2025) 85 (8_Supplement_1): 5469). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07693751 | Phase Ib/II | SOT109 | A Study Testing SOT109 for the First Time in Patients, to Assess How Safe SOT109 is, How Well it Works, and How the Body Handles it in Patients With Advanced Colorectal Cancer That Can Not be Removed by Surgery or is Metastatic | Not yet recruiting | USA | 1 |